Valuation: Turn Therapeutics Inc.

Market Cap 217M 190M 176M 164M 309M 20.56B 314M 2.11B 818M 10.15B 817M 799M 35.35B P/E 2024 *
-
P/E 2025 -34.2x
Enterprise Value 212M 186M 172M 160M 302M 20.09B 307M 2.06B 799M 9.91B 798M 780M 34.53B EV / Sales 2024 *
-
EV / Sales 2025 -
Free-Float
36.26%
Yield 2024 *
-
Yield 2025 -
1 day+5.64%
1 week+21.87%
1 month+40.38%
3 months+128.12%
6 months+85.28%
Current year+85.28%
1 week 5.84
Extreme 5.8403
7.39
1 month 4.83
Extreme 4.8273
7.39
Current year 3.01
Extreme 3.01
7.39
1 year 2.57
Extreme 2.5701
26.5
3 years 2.57
Extreme 2.5701
26.5
5 years 2.57
Extreme 2.5701
26.5
10 years 2.57
Extreme 2.5701
26.5
Manager TitleAgeSince
Chief Executive Officer 48 2015-01-05
Director of Finance/CFO 31 2025-04-30
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 48 -
Director/Board Member 46 2018-09-30
Director/Board Member 61 2019-12-31
Date Insider Type Main position Quantity % Market Cap.
06-03Free

Director

71,666 0.2406%
06-03Free

Director

95,000 0.3189%
06-03Free

Director

83,334 0.2798%
Change 5-day change 1-year change 3-year change Capi.($)
+5.64%+21.87% - - 217M
+0.57%+9.00%+71.61%+133.54% 57.65B
-1.32%+17.12%+79.02%+99.82% 55.14B
-1.28%+2.68%-12.60%-13.79% 23.53B
+1.79%+4.38%+5.94%+405.31% 23.11B
-1.93%+11.11%+34.89%-7.86% 18.14B
+1.28%+6.80%+38.61%-29.73% 16.84B
+0.24%+5.98%+23.45%+184.72% 13.68B
+0.14%+9.60%+33.31% - 12.97B
+1.83%+4.58%+77.42%+132.45% 12.38B
Average +0.70%+7.30%+39.07%+113.06% 23.37B
Weighted average by Cap. -0.06%+4.89%+48.50%+116.88%

Financials

2024 2025
Net sales - -
Net income -1.77M -1.55M -1.43M -1.33M -2.51M -167M -2.56M -17.14M -6.65M -82.51M -6.64M -6.5M -287M -3.19M -2.8M -2.58M -2.41M -4.54M -302M -4.62M -30.96M -12.02M -149M -12M -11.73M -519M
Net Debt -752K -658K -607K -566K -1.07M -71.06M -1.09M -7.28M -2.83M -35.07M -2.82M -2.76M -122M -5M -4.37M -4.04M -3.77M -7.09M -472M -7.22M -48.42M -18.8M -233M -18.77M -18.35M -812M
Logo Turn Therapeutics Inc.
Turn Therapeutics Inc. is a pharmaceutical and medical device development company built around a proprietary platform of technology designed to enhance drug performance. Its patented mixing process-commercially referred to as PermaFusion-enables stable suspension of polar, water-soluble active pharmaceutical ingredients (APIs) in oil-based carriers without the use of emulsifiers. Its primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis. Its products and programs include GX-03/Hexagen for Wounds (Hexagen (K160872)), GX-03/Hexagen for Derm (AtopX (K171191)), Sterile Gauze Impregnated with GX-03/Hexagen (XEAL (K183681)), Sterile Collagen/Hexagen Powder (FleX Product), GX-03/Hexagen for Moderate-Severe Eczema, and GX-03/Hexagen for Onychomycosis. GX-03/Hexagen for Wounds (Hexagen (K160872)) is a medical device for treating wounds and burns. GX-03/Hexagen for Derm (AtopX (K171191)) is a medical device for managing dermatitis.
Employees
2
Date Price Change Volume
26-06-30 US$7.300 +5.64% 59,162
26-06-29 US$6.910 -0.29% 28,558
26-06-26 US$6.930 +1.61% 113,337
26-06-25 US$6.820 +11.99% 49,022
26-06-24 US$6.090 +1.67% 28,340

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TTRX Stock